<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04722107</url>
  </required_header>
  <id_info>
    <org_study_id>ZVS101e-01</org_study_id>
    <nct_id>NCT04722107</nct_id>
  </id_info>
  <brief_title>The Gene Replacement Therapy by rAAV2/8-hCYP4V2</brief_title>
  <official_title>A Safety Study of The Gene Replacement Therapy by rAAV2/8-hCYP4V2 Following a Single Subretinal Administration in The Patients of Bietti's Crystalline Dystrophy (BCD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives: To evaluate the safety of The Gene Replacement Therapy by rAAV2/8-hCYP4V2&#xD;
      Following a Single Subretinal Administration in The Patients of Bietti's Crystalline&#xD;
      Dystrophy (BCD).&#xD;
&#xD;
      Secondary Objectives: To explore the efficacy of The Gene Replacement Therapy by&#xD;
      rAAV2/8-hCYP4V2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Safety Study of The Gene Replacement Therapy by rAAV2/8-hCYP4V2 Following a Single&#xD;
      Subretinal Administration in The Patients of Bietti's Crystalline Dystrophy (BCD)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the safety of The Gene Replacement Therapy by rAAV2/8-hCYP4V2</measure>
    <time_frame>In15 months</time_frame>
    <description>Incidence of AE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the efficacy of The Gene Replacement Therapy by rAAV2/8-hCYP4V2.</measure>
    <time_frame>In15 months</time_frame>
    <description>Changes of functional indexes, behavioral indexes and morphological indexes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Bietti's Crystalline Dystrophy</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gene Replacement Therapy by rAAV2/8-hCYP4V2</intervention_name>
    <description>Gene Replacement Therapy by rAAV2/8-hCYP4V2</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Are 18 years and older;&#xD;
&#xD;
          -  2) Are diagnosed of Bietti's crystalline dystrophy (BCD);&#xD;
&#xD;
          -  3) Molecular diagnosis confirmed due to CYP4V2 mutations (two pathogenic mutation);&#xD;
&#xD;
          -  4) Are met with the target eye inclusion criterion;&#xD;
&#xD;
          -  5) Agree to take effective contraceptive measures from the beginning of the study to 1&#xD;
             year after the administration;&#xD;
&#xD;
          -  6) Are voluntarily participated in the study and signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Have insufficient viable retinal photoreceptor cells. Retinal photoreceptor cells&#xD;
             are less than 1D , or areas of retina with thickness measurements less than 100 µm；&#xD;
&#xD;
          -  2) Existing or pre-existing of choroidal neovascular (CNV) lesions that were secondary&#xD;
             to BCD, or other eye conditions interfering with the surgery or the interpretation of&#xD;
             the clinical endpoint, in the investigators' opinion;&#xD;
&#xD;
          -  3) Prior use of medicines which may affect the experimental observation within the 6&#xD;
             months before screening (e.g. Lucentis, Avastin Eylea, Conbercept, Triamcinolone&#xD;
             acetonide, Corticosteroids)；&#xD;
&#xD;
          -  4) Prior intraocular surgery in the target eye (e.g. PDT, pars plana vitrectomy,&#xD;
             periocular vascular bypass surgery), or requirement of intraocular surgery during the&#xD;
             clinical study (e.g. cataract surgery, laser therapy of retina);&#xD;
&#xD;
          -  5) Use of or potentially require of systemic medications that may cause eye damage&#xD;
             (e.g. psoralen, risselinic acid, tamoxifen)；&#xD;
&#xD;
          -  6) Known hypersensitivity to any ingredient of clinical trial medicine, or allergies&#xD;
             (with an allergy history to two or more kinds of medicines or foods);&#xD;
&#xD;
          -  7) Abnormal physical examination, vital signs, laboratory examination (e.g. blood&#xD;
             routine, urine routine, blood biochemistry, coagulation function, immunologic test,&#xD;
             pregnacy test), or other related indicators which have a clinical significance&#xD;
             considered by the investigators；&#xD;
&#xD;
          -  8) Have any medical conditions or medical history which may have an effect on the&#xD;
             safety or the intracorporal process of drugs, especially medical history of&#xD;
             angiocarpy, liver, kidney, internal secretion, digestive tract, lung, nerve, blood,&#xD;
             tumor, immune or metabolic disorders, which have a clinical significance considered by&#xD;
             the investigators；&#xD;
&#xD;
          -  9) Participation in any medicine or medical device clinical trials within 3 months&#xD;
             prior to enrollment;&#xD;
&#xD;
          -  10) Neutralizing antibodies to rAAV&gt; 1:1000 by immunologic test;&#xD;
&#xD;
          -  11) For females in pregnancy or lactation period;&#xD;
&#xD;
          -  12) Any other conditions which leads the investigator to determine the participant is&#xD;
             unsuitable for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>wenbin Wei, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vice President of Beijing Tongren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>wenbin Wei, Doctor</last_name>
    <phone>13701255115</phone>
    <email>tr_weiwenbin@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xiuli Zhao, Doctor</last_name>
    <phone>18811612056</phone>
    <email>xiulizhao@medmail.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wenbin wei, Doctor</last_name>
      <phone>13701255115</phone>
      <email>tr_weiwenbin@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Dystrophies, Hereditary</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

